160 related articles for article (PubMed ID: 7840599)
1. In vitro activity of DU-6859a against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of three of the newer quinolones against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
[TBL] [Abstract][Full Text] [Related]
6. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.
Kato N; Kato H; Tanaka-Bando K; Watanabe K; Ueno K
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S31-5. PubMed ID: 8953104
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Cormican MG; Marshall SA; Jones RN
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
[TBL] [Abstract][Full Text] [Related]
10. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.
Nakane T; Iyobe S; Sato K; Mitsuhashi S
Antimicrob Agents Chemother; 1995 Dec; 39(12):2822-6. PubMed ID: 8593031
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of faropenem against 579 strains of anaerobic bacteria.
Wexler HM; Molitoris D; St John S; Vu A; Read EK; Finegold SM
Antimicrob Agents Chemother; 2002 Nov; 46(11):3669-75. PubMed ID: 12384389
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study.
Finegold SM; Molitoris E; Reeves D; Wexler HM
J Antimicrob Chemother; 1991 Dec; 28 Suppl C():25-30. PubMed ID: 1664827
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Apr; 41(4):847-9. PubMed ID: 9087503
[TBL] [Abstract][Full Text] [Related]
14. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
15. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
Thomson KS; Sanders CC
J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
[TBL] [Abstract][Full Text] [Related]
16. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
[TBL] [Abstract][Full Text] [Related]
17. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
18. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
Kitamura A; Hoshino K; Kimura Y; Hayakawa I; Sato K
Antimicrob Agents Chemother; 1995 Jul; 39(7):1467-71. PubMed ID: 7492087
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
Saito H; Tomioka H; Sato K; Dekio S
Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
